# HYDROCEPHALUS ASSOCIATION & CINCINNATI CHILDREN'S HOSPITAL

# RESEARCH WORKSHOP

Developing Non-Invasive Hydrocephalus Therapies:

Advancing Towards Clinical Trials



Friday, April 12, 2024

8:00 AM - 5:30 PM

Saturday, April 13, 2024

8:00 AM - 2:00 PM

#### Cincinnati Children's Hospital

T Building Conference Room 240 Albert Sabin Way Cincinnati, OH 45229



Attendees will stay at the Graduate Hotel, 151 Goodman Street, Cincinnati, Ohio 45219 (Walking distance to workshop venue)





# Planning Committee James (Pat) McAllister, PhD Washington University in St. Louis

Bonnie Blazer-Yost, PhD Indiana University

**Ramin Eskandari, MD** Medical University of South Carolina

# **Francesco Mangano, DO**Cincinnati Children's Hospital Medical Center

# **June Goto, PhD**Cincinnati Children's Hospital Medical Center

**Lauren Jantzie, PhD**Johns Hopkins University

Maria Garcia Bonilla, PhD Virginia Commonwealth University

Mark Johnson, MD, PhD UMass Chan Medical School

### **WELCOME LETTER**

From HA President and CEO, Diana Gray and Cincinnati Children's host, Dr. Francesco Mangano

Welcome to the Hydrocephalus Association (HA) and Cincinnati Children's Hospital 2024 Research Workshop.

This workshop builds directly upon the momentum of the 2023 workshop, responding to the urgent need for non-invasive therapies for hydrocephalus. Your participation emphasizes our shared dedication to pushing the boundaries of hydrocephalus research. We aim to leverage this collective energy to foster innovation and address HA's critical patient-centered <a href="Community Research Priorities">Community Research Priorities</a> with a particular emphasis on:

- Developing new treatments that do not require brain surgery to manage hydrocephalus.
- Developing new one-time treatments to manage hydrocephalus (i.e. permanent treatments that do not require additional interventions).
- Developing ways to prevent the development of hydrocephalus.

Our focus is on advancing non-invasive treatments for hydrocephalus through consensus models, endpoint measurements, and external collaborations. The program was carefully created to contribute significantly to the advancement of preclinical and clinical trials and provide foresight for regulatory and funding processes. There will be direct opportunities to engage in conversations with governance agencies and industry liaisons, offering a valuable chance to gain insights into FDA expectations and leverage the expertise of companies.

We will integrate the priorities identified in this workshop with those from the 2023 workshop, resulting in the creation of a comprehensive white paper slated for publication in a peer-reviewed journal. The outcomes of this workshop will contribute significantly to our mission of finding a cure for hydrocephalus and improving the lives of those impacted by the condition.

Thank you for being an integral part of this critical initiative. Together, we are driving progress and innovation in hydrocephalus research.

Sincerely,

Diana Gray, MA

President and Chief Executive Officer Hydrocephalus Association Francesco Mangano, DO, FACS,

FAAP, FACOS

Division Chief of Pediatric Neurosurgery Cincinnati Children's Hospital Medical Ctr

## HA & CCHMC Research Workshop Agenda

### Friday, April 12, 2024

8:00 AM Breakfast

8:20 AM Opening and welcoming remarks

Francesco Mangano, DO

Cincinnati Children's Hospital Medical Center

Diana Gray, MA

Hydrocephalus Association

Monica Chau, PhD

Hydrocephalus Association

### SESSION 1: CREATING SCIENTIFIC CONSENSUS

WHAT ARE THE IDEAL ANIMAL MODELS AND TECHNIQUES TO INDUCE HYDROCEPHALUS?

9:25 AM MODERATOR: Pat McAllister, PhD

Washington University in St. Louis
Introduction to the round table format

9:30 AM Acquired hydrocephalus models overviews

Marc del Bigio, MD, PhD

University of Manitoba

Animal models of hydrocephalus: what is their translational utility for development of

therapies?

9:45 AM SPEAKERS

Pat McAllister, PhD

Washington University in St. Louis

Kaolin-induced hydrocephalus models

Jose Peiro, MD, PhD

Cincinnati Children's Hospital Medical Center Fetal intracisternal BioGlue for a new model of obstructive hydrocephalus in large animal

research

Lauren Jantzie, PhD

Johns Hopkins University

The essential role of inflammation in modeling

PHHP secondary to IVH

Brandon Miller, MD, PhD

**UTHealth Houston** 

Using blood vs. hemoglobin for IVH research

10:15 AM Consensus building: Open discussion

10:40 AM Break

10:55 AM Genetic models overviews

June Goto, PhD

Cincinnati Children's Hospital Medical Center Genetic models of congenital hydrocephalus

Mark Johnson, MD, PhD

UMass Memorial Health;

Decoding iNPH: Mechanistic Insights from

**Genetically Engineered Mice** 

11:10 AM Consensus building: Open discussion

### WHAT ENDPOINT MEASUREMENTS SHOULD WE BE USING?

**MODERATOR: Bonnie Blazer Yost, PhD** 

Indiana University – Purdue University

Indianapolis (IUPUI)

11:25 AM Harriet Kamendi, PhD

Kandih BioScience

FDA toxicology expectations

Charles V. Vorhees, PhD

University of Cincinnati

Behavioral testing paradigms as hydrocephalus endpoint measures

Diana Lindquist, PhD

Cincinnati Children's Hospital Medical Center Translating MRI to the preclinical realm: advanced rodent neuroimaging for the evaluation of hydrocephalus

11:45 AM Consensus building: Open discussion

12:10 PM **Lunch** 

#### **SESSION 2: PATIENT PERSPECTIVE**

### WHAT MOTIVATES PATIENTS TO PARTICIPATE IN CLINICAL STUDIES?

MODERATOR: Samantha Lanjewar, PhD

Hydrocephalus Association

1:10 PM Denise Berman, MS

Alejandro Rojas, PhD

Ananke Therapeutics

Lynn Beirl, BA

Flourishing in Mid-Life Women's

Hydrocephalus Group

#### HA & CCHMC Research Workshop Agenda (cont.)

### SESSION 3: LESSONS FROM CURRENT & PAST CLINICAL TRIALS

MODERATOR: David Limbrick, MD, PhD

Virginia Commonwealth University

1:50 PM David Limbrick, MD, PhD

Virginia Commonwealth University ESTHI trial and lessons learned

2:15 PM Francesco Mangano, DO

Cincinnati Children's Hospital Medical Center

Governance in clinical trials: DSMB

2:30 PM Robin Ohls, MD, PhD

University of Utah

Phase I-III trials in preterm infants using

Darbepoetin

2:55 PM Bonnie Blazer Yost, PhD

Indiana University – Purdue University

Indianapolis (IUPUI)

Perspectives from kidney disease clinical trials and navigating the patent process for

hydrocephalus treatment

3:20 PM Break

3:35 PM Shenandoah (Dody) Robinson, MD

Johns Hopkins University

Overcoming regulatory barriers on the way to Phase I: A clinical trial of EPO+MLT in preterm

infants with severe IVH

4:00 PM Mark Luciano, MD

Johns Hopkins University

Minority access to Neurosurgery: iNPH as a

case study

#### **SESSION 4: INDUSTRY PERSPECTIVE**

**MODERATOR: Francesco Mangano, DO** 

4:25 PM Mike McBreen

Integra LifeSciences

How we partner to help patients: an industry

perspective

### SESSION 5: TAKEAWAYS ON HOW TO MOVE TO CLINICAL TRIALS AND BEYOND

5:00 PM MODERATOR: Lauren Jantzie, PhD

Johns Hopkins University

How can we better design preclinical trials with

a focus towards clinical translation?

5:20 PM End of program day

6:30 PM Group dinner (invitation only)

hosted by Integra LifeSciences

Via Vite Ristorante 520 Vine Street Cincinnati, OH 45202 (513) 721-8483

#### HA & CCHMC Research Workshop Agenda (cont.)

#### Day 2, April 13

8:00 AM Breakfast

9:00 AM Opening and welcoming remarks

### SESSION 6: ROADMAP TO ADVANCING TO CLINICAL TRIALS AND BEYOND

#### **Regulatory Aspect**

**MODERATOR: Ramin Eskandari, MD** *Medical University of South Carolina (MUSC)* 

8:30 AM FDA speaker

Food and Drug Administration (FDA)

Center for Drug Evaluation and Research (CDER)

Advancing to clinical trials

9:00 AM Bruce Mackler, PhD, JD

The drug discovery process and the role

of the academic researcher

9:25 AM Harriet Kamendi, PhD

Kandih BioScience

FDA toxicology: planning preclinical studies

#### **University IP offices**

9:50 AM Carole Burns, PhD

UMass Chan Medical School BRIDGE Office of Innovation and Business Development Bridging the Gap: A new paradigm for advancing academic innovation

10:15 AM Justin Levy, JD & Jon Brophy, MSE

Cincinnati Children's Innovation Ventures
Technology licensing basics for medical
devices and therapeutics in hydrocephalus

10:40 AM Break

#### **SESSION 7: FUNDERS' SUPPORT**

#### **Government Funding**

**MODERATOR: Carolyn Harris, PhD** 

Wayne State University

11:00 AM Jill Morris, PhD

National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
NINDS funding opportunities supporting

translational research

11:25 AM Cecilia Dupecher, PhD

Department of Defense (DoD), Congressionally Directed Medical Research Programs (CDMRP) Department of Defense, Congressionally Directed Medical Research Programs and

support for clinical trials

#### **Private Funding**

11:50 AM Scott Davis, PhD

The Sontag Foundation

The role of investment groups to advance

therapies

12:15 PM Monica Chau, PhD

Hydrocephalus Association


Hydrocephalus Association's role in


supporting scientists

12:35 PM Lunch and networking

2:00 PM End of workshop program

## Notes







#### **HYDROCEPHALUS ASSOCIATION**









f 🏏 🖸 in 🕞 @hydroassoc